Antonio Pazzola

Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

Fabrice Barlési, Arnaud Scherpereel, Achim Rittmeyer et al. · Journal of Clinical Oncology · 2013 · 327 citations

Medicine, Oncology, Pharmacology +12

Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Fabrice Barlési, Arnaud Scherpereel, R. Gervais et al. · Annals of Oncology · 2014 · 169 citations · Full text

Medicine, Oncology, Pharmacology +11

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Elena Verzoni, Giacomo Cartenì, Enrico Cortesi et al. · Journal for ImmunoTherapy of Cancer · 2019 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study

Grazia Palomba, Valentina Doneddu, Antonio Cossu et al. · Journal of Translational Medicine · 2016 · 59 citations · Full text

Medicine, Oncology, Pathology +17